| Nome |
# |
|
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis, file dd9e0c65-4484-1e9c-e053-3a05fe0a45ef
|
163
|
|
A rare case of IgM-Multiple Myeloma, file dd9e0c65-4183-1e9c-e053-3a05fe0a45ef
|
143
|
|
LIGHT/TNFSF14 as a new biomarker of bone disease in multiple myeloma patients experiencing therapeutic regimens, file dd9e0c65-6c86-1e9c-e053-3a05fe0a45ef
|
69
|
|
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials, file 1a03843b-1763-4fd3-9049-ce4aff88d151
|
38
|
|
Case Report: A case of IgD lambda/lambda Multiple Myeloma in patient with acute renal failure and without monoclonal spike in serum electrophoresis, file 0c5ecdb1-295e-48cc-8581-a30b8eaf4da8
|
36
|
|
DEDALO: PHASE II STUDY OF DARATUMUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE (DPD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND 17P DELETION, file d3da47dd-6bdb-45d6-80b7-3234235c6040
|
25
|
|
Light/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease., file dd9e0c64-5753-1e9c-e053-3a05fe0a45ef
|
14
|
|
SARS-CoV-2 Infection Incidence and Outcome Before and After Full Vaccination in Patients With Monoclonal Gammopathy of Undetermined Significance, file df13bdc0-fa56-4e29-8390-f0edeaa333ea
|
14
|
|
CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: THE REAL LIFE EXPERIENCE OF RETE EMATOLOGICA PUGLIESE (REP), file dd9e0c6a-7d60-1e9c-e053-3a05fe0a45ef
|
12
|
|
What Is New in the Treatment of Smoldering Multiple Myeloma?, file dd9e0c6b-52f5-1e9c-e053-3a05fe0a45ef
|
12
|
|
TRAIL effect on osteoclast formation in physiological and pathological conditions, file dd9e0c62-7656-1e9c-e053-3a05fe0a45ef
|
11
|
|
SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma, file dd9e0c6b-93df-1e9c-e053-3a05fe0a45ef
|
10
|
|
null, file dd9e0c67-2c7b-1e9c-e053-3a05fe0a45ef
|
8
|
|
Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM), file 8415c38f-2e14-4fb2-b3b7-ef1429d95b11
|
6
|
|
The role of multiparameter flow cytometry in the work-up of IGM-monoclonal gammopathies, file dd9e0c65-47b3-1e9c-e053-3a05fe0a45ef
|
6
|
|
Analysis of percent identity of IGHV mutation as prognostic factor in CLL patients treated with fludarabine, cyclofosfamide and rituximab: a single centre experience, file dd9e0c65-4981-1e9c-e053-3a05fe0a45ef
|
6
|
|
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis, file dd9e0c65-4ea5-1e9c-e053-3a05fe0a45ef
|
6
|
|
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies, file dd9e0c68-e6ab-1e9c-e053-3a05fe0a45ef
|
6
|
|
Cytokine Signature in Schnitzler Syndrome: Proinflammatory Cytokine Production Associated to Th Suppression, file dd9e0c6a-9f99-1e9c-e053-3a05fe0a45ef
|
6
|
|
Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor, file dd9e0c6b-52b2-1e9c-e053-3a05fe0a45ef
|
6
|
|
Schnitzler syndrome: validation and applicability of diagnostic criteria in real-life patients, file dd9e0c64-082d-1e9c-e053-3a05fe0a45ef
|
5
|
|
A role of light as potential biomarker for progression of smoldering to symptomatic multiple myeloma, file dd9e0c65-47b1-1e9c-e053-3a05fe0a45ef
|
5
|
|
Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function, file dd9e0c66-beb3-1e9c-e053-3a05fe0a45ef
|
5
|
|
Implications of interleukin-6 (Il-6)-blockade for severe covid-19 infection in patients with multiple myeloma, file dd9e0c6b-6f14-1e9c-e053-3a05fe0a45ef
|
5
|
|
Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf, file dd9e0c6b-7155-1e9c-e053-3a05fe0a45ef
|
5
|
|
Humoral Immune Response after anti-SARS-CoV-2 Vaccine "Booster" Dose in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS), file 597f931d-0795-48f6-9e5a-1586b8d51af9
|
4
|
|
Myeloma cells suppress osteoblasts through sclerostin secretion, file dd9e0c63-10fa-1e9c-e053-3a05fe0a45ef
|
4
|
|
Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients, file dd9e0c64-b738-1e9c-e053-3a05fe0a45ef
|
4
|
|
LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE (RD) AS FIRST LINE TREATMENT OF NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE TO STEM CELL TRANSPLANTATION: REAL LIFE ITALIAN EXPERIENCE, file dd9e0c69-76b2-1e9c-e053-3a05fe0a45ef
|
4
|
|
ANALYSIS OF PROGNOSTIC FACTORS AND TIME TO FIRST TREATMENT IN YOUNG PATIENTS (<55 YEARS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A SINGLE CENTER EXPERIENCE, file dd9e0c69-9ee8-1e9c-e053-3a05fe0a45ef
|
4
|
|
Incidence and outcome of SARS-CoV-2 infection in patients with monoclonal gammopathy of undetermined significance: a case-control study, file 6c502674-a02c-4353-a095-cdee57fe1529
|
3
|
|
Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients., file dd9e0c64-f5cb-1e9c-e053-3a05fe0a45ef
|
3
|
|
Schnitzler's syndrome: monoclonal gammopathy associated with chronic urticaria, file dd9e0c64-f7a9-1e9c-e053-3a05fe0a45ef
|
3
|
|
Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenstrom Macroglobulinemia, file dd9e0c65-589a-1e9c-e053-3a05fe0a45ef
|
3
|
|
Real world Italian experience of pomalidomide plus low-dose dexamethasone in the relapsed and refractory myeloma setting: extended follow-up of a retrospective multicenter study by the ‘Rete Ematologica Pugliese E Basilicata’, file dd9e0c65-c9af-1e9c-e053-3a05fe0a45ef
|
3
|
|
DARA-VD VERSUS DARA-RD AS SALVAGE THERAPY FOR PATIENTS WITH MYELOMA. INITIAL FOLLOW-UP OF AN ITALIAN MULTICENTER RETROSPECTIVE CLINICAL EXPERIENCE BY RETE EMATOLOGICA PUGLIESE, file dd9e0c69-90c6-1e9c-e053-3a05fe0a45ef
|
3
|
|
REAL-WORLD ITALIAN EXPERIENCE OF POMALIDOMIDE IN RELAPSED-REFRACTORY MYELOMA: RETROSPECTIVE MULTICENTER STUDY BY THE RETE EMATOLOGICA PUGLIESE AND BASILICATA, file dd9e0c6a-7e4d-1e9c-e053-3a05fe0a45ef
|
3
|
|
Schnitzler's syndrome: diagnosis, treatment, and follow-up., file dd9e0c62-834d-1e9c-e053-3a05fe0a45ef
|
2
|
|
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia, file dd9e0c62-885c-1e9c-e053-3a05fe0a45ef
|
2
|
|
Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I–II GIMEMA trial, file dd9e0c64-0f47-1e9c-e053-3a05fe0a45ef
|
2
|
|
Spontaneous remission of "methotrexate-associated lymphoproliferative disorders" after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature, file dd9e0c64-f82a-1e9c-e053-3a05fe0a45ef
|
2
|
|
Non-treatment-related chronic myeloid leukemia as a second malignancy, file dd9e0c67-437f-1e9c-e053-3a05fe0a45ef
|
2
|
|
Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP), file dd9e0c69-04d7-1e9c-e053-3a05fe0a45ef
|
2
|
|
How Age, Comorbidities and Concomitant Medications Influence Ibrutinib Management and Survival in Waldenstrom Macroglobulinemia, file 2cd06351-a476-4f36-ae69-affc7449b683
|
1
|
|
Anti-endothelial cell antibodies (AECA) in Behcet’s disease, file dd9e0c62-5c9a-1e9c-e053-3a05fe0a45ef
|
1
|
|
Amyloid in bone marrow smears of patients affected by multiple myeloma, file dd9e0c62-763e-1e9c-e053-3a05fe0a45ef
|
1
|
|
Malignant lymphoma involving a Warthin’s tumor: a case with immunophenotypic and gene rearrangement analysis, file dd9e0c62-7989-1e9c-e053-3a05fe0a45ef
|
1
|
|
Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide, file dd9e0c62-81b9-1e9c-e053-3a05fe0a45ef
|
1
|
|
Soluble CD4 and commercial immunoglobulins, file dd9e0c62-cf8d-1e9c-e053-3a05fe0a45ef
|
1
|
|
L’ospite immunocompromesso: un complesso sindromico in espansione. Quadri clinici, aspetti immunologici e prospettive terapeutiche, file dd9e0c63-60e6-1e9c-e053-3a05fe0a45ef
|
1
|
|
Soluble Decoy Receptor 3 (DcR3) modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients, file dd9e0c64-5daa-1e9c-e053-3a05fe0a45ef
|
1
|
|
"Real world" outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: Extended follow-up of a retrospective multicenter study by the "rete ematologica pugliese", file dd9e0c64-d7e6-1e9c-e053-3a05fe0a45ef
|
1
|
|
The formation of osteoclasts in multiple myeloma bone disease patients involves the secretion of solubile decoy receptor 3, file dd9e0c64-f4ec-1e9c-e053-3a05fe0a45ef
|
1
|
|
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts, file dd9e0c64-f4f9-1e9c-e053-3a05fe0a45ef
|
1
|
|
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials, file dd9e0c65-6662-1e9c-e053-3a05fe0a45ef
|
1
|
|
Immunogenicity of two idiotypes with a different immunoglobulin-chain distribution expressed on the same anti-CD4 Mab, file dd9e0c6a-efbb-1e9c-e053-3a05fe0a45ef
|
1
|
|
null, file dd9e0c6b-6ad9-1e9c-e053-3a05fe0a45ef
|
1
|
| Totale |
689 |